Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

OBJECTIVES: The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with human immunodeficiency virus type 1 (PLWH) are unknown. We aimed to assess the immunogenicity and safety of this vaccine in PLWH. METHODS: In this prospective open study, we enrolled 143 PLWH...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy, Itzchak, Wieder-Finesod, Anat, Litchevsky, Vladyslav, Biber, Asaf, Indenbaum, Victoria, Olmer, Liraz, Huppert, Amit, Mor, Orna, Goldstein, May, Levin, Einav Gal, Hod, Tammy, Cohen, Carmit, Lustig, Yaniv, Rahav, Galia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382485/
https://www.ncbi.nlm.nih.gov/pubmed/34438069
http://dx.doi.org/10.1016/j.cmi.2021.07.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382485/
https://www.ncbi.nlm.nih.gov/pubmed/34438069
http://dx.doi.org/10.1016/j.cmi.2021.07.031

Ejemplares similares